Future perspectives in COPD
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/28559 http://dx.doi.org/10.1016/j.rmed.2005.09.014 |
Resumo: | The pathophysiology of chronic obstructive pulmonary disease (COPD) is complex. the development of a multidimensional index-such as the BODE index-provides a means of classifying patients with COPD that also correlates with their prognosis. the individual components of the BODE index-body mass index (B), airflow obstruction (0) dyspnoea (D) and exercise capacity (E)-incorporate the pulmonary as well as the systemic effects seen in patients with COPD. Recent research has focussed on examining these impairments (including those of metabolism and inflammation) more carefully, and determining the effects of treatment on both the systemic and physiological aspects of COPD.Ongoing research initiatives by the public and private sector will contribute to our understanding of the disease processes underlying COPD, our understanding of the benefits associated with commonly used pharmacotherapies, as welt as laying the foundations for the development of new agents and therapeutic tools. Advances in the use of pharmacotherapy have been mirrored by research to better define the benefits associated with pulmonary rehabilitation. Many questions remain to be answered, but a comprehensive approach is now considered essential to the life-tong management of COPD, and will undoubtedly reduce the considerable socio-economic burden of COPD. (c) 2005 Elsevier B.V. All rights reserved. |
id |
UFSP_f7aa4b4503a95e937dfd852bb7764436 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/28559 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Celli, BartolomeGoldstein, RogerJardim, José Roberto [UNIFESP]Knobil, KatharineTufts UnivUniv TorontoUniversidade Federal de São Paulo (UNIFESP)GlaxoSmithKline Inc2016-01-24T12:38:10Z2016-01-24T12:38:10Z2005-12-01Respiratory Medicine. London: W B Saunders Co Ltd, v. 99, p. S41-S48, 2005.0954-6111http://repositorio.unifesp.br/handle/11600/28559http://dx.doi.org/10.1016/j.rmed.2005.09.014WOS000234110100006.pdf10.1016/j.rmed.2005.09.014WOS:000234110100006The pathophysiology of chronic obstructive pulmonary disease (COPD) is complex. the development of a multidimensional index-such as the BODE index-provides a means of classifying patients with COPD that also correlates with their prognosis. the individual components of the BODE index-body mass index (B), airflow obstruction (0) dyspnoea (D) and exercise capacity (E)-incorporate the pulmonary as well as the systemic effects seen in patients with COPD. Recent research has focussed on examining these impairments (including those of metabolism and inflammation) more carefully, and determining the effects of treatment on both the systemic and physiological aspects of COPD.Ongoing research initiatives by the public and private sector will contribute to our understanding of the disease processes underlying COPD, our understanding of the benefits associated with commonly used pharmacotherapies, as welt as laying the foundations for the development of new agents and therapeutic tools. Advances in the use of pharmacotherapy have been mirrored by research to better define the benefits associated with pulmonary rehabilitation. Many questions remain to be answered, but a comprehensive approach is now considered essential to the life-tong management of COPD, and will undoubtedly reduce the considerable socio-economic burden of COPD. (c) 2005 Elsevier B.V. All rights reserved.Tufts Univ, Dept Med, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USAUniv Toronto, Fac Med, Div Resp Med, W Pk Healthcare Ctr, Toronto, ON M6M 2J5, CanadaUniversidade Federal de São Paulo, Dept Pulm Dis, Pneumol Resp Div, BR-04023060 São Paulo, BrazilGlaxoSmithKline Inc, Resp Med Dev Ctr, Res Triangle Pk, NC USAUniversidade Federal de São Paulo, Dept Pulm Dis, Pneumol Resp Div, BR-04023060 São Paulo, BrazilWeb of ScienceS41-S48engW B Saunders Co LtdRespiratory MedicineBODECOPDfluticasone propionateinternational COPDgenetics networkoxidative stresspulmonary rehabilitationsystemic inflammationsalmeteroltiotropiumTORCHUPLIFTFuture perspectives in COPDinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000234110100006.pdfapplication/pdf181250${dspace.ui.url}/bitstream/11600/28559/1/WOS000234110100006.pdfac5b5cce6f176ed6405665f0b9db192dMD51open accessTEXTWOS000234110100006.pdf.txtWOS000234110100006.pdf.txtExtracted texttext/plain30978${dspace.ui.url}/bitstream/11600/28559/2/WOS000234110100006.pdf.txte5d4652a91ef44160fb4f589c8eba674MD52open access11600/285592022-06-02 09:27:29.735open accessoai:repositorio.unifesp.br:11600/28559Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652022-06-02T12:27:29Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Future perspectives in COPD |
title |
Future perspectives in COPD |
spellingShingle |
Future perspectives in COPD Celli, Bartolome BODE COPD fluticasone propionate international COPD genetics network oxidative stress pulmonary rehabilitation systemic inflammation salmeterol tiotropium TORCH UPLIFT |
title_short |
Future perspectives in COPD |
title_full |
Future perspectives in COPD |
title_fullStr |
Future perspectives in COPD |
title_full_unstemmed |
Future perspectives in COPD |
title_sort |
Future perspectives in COPD |
author |
Celli, Bartolome |
author_facet |
Celli, Bartolome Goldstein, Roger Jardim, José Roberto [UNIFESP] Knobil, Katharine |
author_role |
author |
author2 |
Goldstein, Roger Jardim, José Roberto [UNIFESP] Knobil, Katharine |
author2_role |
author author author |
dc.contributor.institution.none.fl_str_mv |
Tufts Univ Univ Toronto Universidade Federal de São Paulo (UNIFESP) GlaxoSmithKline Inc |
dc.contributor.author.fl_str_mv |
Celli, Bartolome Goldstein, Roger Jardim, José Roberto [UNIFESP] Knobil, Katharine |
dc.subject.eng.fl_str_mv |
BODE COPD fluticasone propionate international COPD genetics network oxidative stress pulmonary rehabilitation systemic inflammation salmeterol tiotropium TORCH UPLIFT |
topic |
BODE COPD fluticasone propionate international COPD genetics network oxidative stress pulmonary rehabilitation systemic inflammation salmeterol tiotropium TORCH UPLIFT |
description |
The pathophysiology of chronic obstructive pulmonary disease (COPD) is complex. the development of a multidimensional index-such as the BODE index-provides a means of classifying patients with COPD that also correlates with their prognosis. the individual components of the BODE index-body mass index (B), airflow obstruction (0) dyspnoea (D) and exercise capacity (E)-incorporate the pulmonary as well as the systemic effects seen in patients with COPD. Recent research has focussed on examining these impairments (including those of metabolism and inflammation) more carefully, and determining the effects of treatment on both the systemic and physiological aspects of COPD.Ongoing research initiatives by the public and private sector will contribute to our understanding of the disease processes underlying COPD, our understanding of the benefits associated with commonly used pharmacotherapies, as welt as laying the foundations for the development of new agents and therapeutic tools. Advances in the use of pharmacotherapy have been mirrored by research to better define the benefits associated with pulmonary rehabilitation. Many questions remain to be answered, but a comprehensive approach is now considered essential to the life-tong management of COPD, and will undoubtedly reduce the considerable socio-economic burden of COPD. (c) 2005 Elsevier B.V. All rights reserved. |
publishDate |
2005 |
dc.date.issued.fl_str_mv |
2005-12-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T12:38:10Z |
dc.date.available.fl_str_mv |
2016-01-24T12:38:10Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Respiratory Medicine. London: W B Saunders Co Ltd, v. 99, p. S41-S48, 2005. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/28559 http://dx.doi.org/10.1016/j.rmed.2005.09.014 |
dc.identifier.issn.none.fl_str_mv |
0954-6111 |
dc.identifier.file.none.fl_str_mv |
WOS000234110100006.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1016/j.rmed.2005.09.014 |
dc.identifier.wos.none.fl_str_mv |
WOS:000234110100006 |
identifier_str_mv |
Respiratory Medicine. London: W B Saunders Co Ltd, v. 99, p. S41-S48, 2005. 0954-6111 WOS000234110100006.pdf 10.1016/j.rmed.2005.09.014 WOS:000234110100006 |
url |
http://repositorio.unifesp.br/handle/11600/28559 http://dx.doi.org/10.1016/j.rmed.2005.09.014 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Respiratory Medicine |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
S41-S48 |
dc.publisher.none.fl_str_mv |
W B Saunders Co Ltd |
publisher.none.fl_str_mv |
W B Saunders Co Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/28559/1/WOS000234110100006.pdf ${dspace.ui.url}/bitstream/11600/28559/2/WOS000234110100006.pdf.txt |
bitstream.checksum.fl_str_mv |
ac5b5cce6f176ed6405665f0b9db192d e5d4652a91ef44160fb4f589c8eba674 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764137253568512 |